Methotrexate for induction of remission in refractory Crohn's disease (Q24202436)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Methotrexate for induction of remission in refractory Crohn's disease (English)

0 references

0 references

1 reference

4

Brian G Feagan

0 references

author name string

John WD McDonald

series ordinal

1

0 references

David J Tsoulis

series ordinal

2

0 references

John K MacDonald

series ordinal

3

0 references

publication date

12 December 2012

0 references

published in

0 references

cites work

Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn's disease: a controlled pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Low-dose oral methotrexate in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Methotrexate in refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Pharmacokinetics of subcutaneous methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Cyclosporine for induction of remission in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Methotrexate for induction of remission in refractory Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021

Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohn's disease: results from a prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021

A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021

Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021

Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021

Methotrexate for the treatment of refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB3

7 January 2021